ARROWHEAD PHARMACEUTICALS IN (ARWR)

US04280A1007 - Common Stock

18.96  -0.57 (-2.92%)

After market: 19.02 +0.06 (+0.32%)

Fundamental Rating

2

Overall ARWR gets a fundamental rating of 2 out of 10. We evaluated ARWR against 565 industry peers in the Biotechnology industry. ARWR may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ARWR is valued expensive at the moment.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

ARWR had negative earnings in the past year.
ARWR had a negative operating cash flow in the past year.
ARWR had negative earnings in each of the past 5 years.
ARWR had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

ARWR's Return On Assets of -52.60% is in line compared to the rest of the industry. ARWR outperforms 46.26% of its industry peers.
ARWR's Return On Equity of -323.27% is on the low side compared to the rest of the industry. ARWR is outperformed by 75.80% of its industry peers.
Industry RankSector Rank
ROA -52.6%
ROE -323.27%
ROIC N/A
ROA(3y)-34.95%
ROA(5y)-28.18%
ROE(3y)-147.71%
ROE(5y)-99.18%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ARWR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

ARWR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARWR has been increased compared to 1 year ago.
ARWR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ARWR is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -1.63, we must say that ARWR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ARWR (-1.63) is comparable to the rest of the industry.
A Debt/Equity ratio of 2.12 is on the high side and indicates that ARWR has dependencies on debt financing.
ARWR's Debt to Equity ratio of 2.12 is on the low side compared to the rest of the industry. ARWR is outperformed by 81.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.12
Debt/FCF N/A
Altman-Z -1.63
ROIC/WACCN/A
WACC10.84%

2.3 Liquidity

ARWR has a Current Ratio of 6.74. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
ARWR's Current ratio of 6.74 is fine compared to the rest of the industry. ARWR outperforms 66.37% of its industry peers.
ARWR has a Quick Ratio of 6.74. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.74, ARWR is doing good in the industry, outperforming 66.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.74
Quick Ratio 6.74

More info and screens

4

3. Growth

3.1 Past

ARWR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -160.94%.
The Revenue for ARWR has decreased by -98.52% in the past year. This is quite bad
The Revenue for ARWR have been decreasing by -53.80% on average. This is quite bad
EPS 1Y (TTM)-160.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.31%
Revenue 1Y (TTM)-98.52%
Revenue growth 3Y-70.5%
Revenue growth 5Y-53.8%
Sales Q2Q%-100%

3.2 Future

ARWR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.18% yearly.
The Revenue is expected to grow by 72.72% on average over the next years. This is a very strong growth
EPS Next Y33.1%
EPS Next 2Y12.58%
EPS Next 3Y12.69%
EPS Next 5Y20.18%
Revenue Next Year133.22%
Revenue Next 2Y90.83%
Revenue Next 3Y71.31%
Revenue Next 5Y72.72%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARWR. In the last year negative earnings were reported.
Also next year ARWR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ARWR's earnings are expected to grow with 12.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.58%
EPS Next 3Y12.69%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARWR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARROWHEAD PHARMACEUTICALS IN

NASDAQ:ARWR (12/27/2024, 8:03:58 PM)

After market: 19.02 +0.06 (+0.32%)

18.96

-0.57 (-2.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-26 2024-11-26/amc
Earnings (Next)02-04 2025-02-04/amc
Inst Owners80.3%
Inst Owner Change-0.76%
Ins Owners4.31%
Ins Owner Change1.8%
Market Cap2.36B
Analysts78.1
Price Target48.38 (155.17%)
Short Float %8.47%
Short Ratio6.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-86.71%
Min EPS beat(2)-145.24%
Max EPS beat(2)-28.19%
EPS beat(4)0
Avg EPS beat(4)-184.34%
Min EPS beat(4)-515.69%
Max EPS beat(4)-28.19%
EPS beat(8)1
Avg EPS beat(8)-108.26%
EPS beat(12)2
Avg EPS beat(12)-59.43%
EPS beat(16)2
Avg EPS beat(16)-99.05%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-97.05%
Min Revenue beat(4)-100%
Max Revenue beat(4)-88.2%
Revenue beat(8)1
Avg Revenue beat(8)-46.57%
Revenue beat(12)2
Avg Revenue beat(12)-38.69%
Revenue beat(16)3
Avg Revenue beat(16)-35.33%
PT rev (1m)0.3%
PT rev (3m)0.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-57.43%
EPS NY rev (1m)22.21%
EPS NY rev (3m)23.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.4%
Revenue NY rev (1m)16.06%
Revenue NY rev (3m)16.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 664.37
P/FCF N/A
P/OCF N/A
P/B 12.72
P/tB 13.34
EV/EBITDA N/A
EPS(TTM)-5.01
EYN/A
EPS(NY)-3.35
Fwd EYN/A
FCF(TTM)-4.86
FCFYN/A
OCF(TTM)-3.72
OCFYN/A
SpS0.03
BVpS1.49
TBVpS1.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.6%
ROE -323.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.95%
ROA(5y)-28.18%
ROE(3y)-147.71%
ROE(5y)-99.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 760.79%
Cap/Sales 3983.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.74
Quick Ratio 6.74
Altman-Z -1.63
F-Score2
WACC10.84%
ROIC/WACCN/A
Cap/Depr(3y)894.03%
Cap/Depr(5y)633.96%
Cap/Sales(3y)1359.68%
Cap/Sales(5y)821.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-160.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.31%
EPS Next Y33.1%
EPS Next 2Y12.58%
EPS Next 3Y12.69%
EPS Next 5Y20.18%
Revenue 1Y (TTM)-98.52%
Revenue growth 3Y-70.5%
Revenue growth 5Y-53.8%
Sales Q2Q%-100%
Revenue Next Year133.22%
Revenue Next 2Y90.83%
Revenue Next 3Y71.31%
Revenue Next 5Y72.72%
EBIT growth 1Y-193.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.01%
EBIT Next 3Y5.39%
EBIT Next 5Y18.88%
FCF growth 1Y-82.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-200.75%
OCF growth 3YN/A
OCF growth 5YN/A